logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Kurome Therapeutics Closes $15 Million Series A Financing To Develop Targeted Kinase Inhibitors For Treatment Of Hematopoietic Cancers

Kurome Therapeutics Closes $15 Million Series A Financing To Develop Targeted Kinase Inhibitors For Treatment Of Hematopoietic Cancers

06/10/21, 11:09 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcincinnati
Money raised
$15 million
Round Type
series a
Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, today announced the closing of a $15 million Series A financing. The round was co-led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors.

Company Info

Company
Kurome Therapeutics
Location
cincinnati, ohio, united states
Additional Info
Kurome® Therapeutics is a preclinical stage company developing novel therapies that subvert cancer’s ability to evade treatment. Founded on research at Cincinnati Children’s Hospital Medical Center in collaboration with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), Kurome is developing a series of combined IRAK1/4 and panFLT3 inhibitors to target cancer cells that have co-opted IRAK1/4-mediated immune signaling pathways to survive.
G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.